

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Piroplasmosis in Italian Standardbred Horses: 15 Years of Surveillance Data

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Padalino, B., Rosanowski, S.M., Di Bella, C., Lacinio, R., Rubino, G.T.R. (2019). Piroplasmosis in Italian Standardbred Horses: 15 Years of Surveillance Data. JOURNAL OF EQUINE VETERINARY SCIENCE, 83(December 2019), 1-6 [10.1016/j.jevs.2019.102813].

Availability:

This version is available at: <https://hdl.handle.net/11585/715426> since: 2020-01-20

Published:

DOI: <http://doi.org/10.1016/j.jevs.2019.102813>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

1 **PIROPLASMOSIS IN ITALIAN STADARDBRED HORSES: 15 YEARS OF**
2 **SURVEILLANCE DATA**

3 B. Padalino^{a*}, S.M. Rosanowski^b, C. Di Bella^c, R. Lacinio^c. and G.T.R. Rubino^c

4 ^a *Department of Veterinary Medicine, University of Bari. Bari, Italy;*

5 ^b *Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong,*
6 *HKSAR*

7 ^c *Department of Emergency and Organ Transplantation, University of Bari, Italy*

8 Corresponding author:

9 Barbara Padalino

10 Department of Veterinary Medicine, University of Bari, Str. Prov. for Casamassima Km 3, 70010
11 Valenzano (Bari), Italy

12 e-mail: *barbara.padalino@uniba.it*

13

14 Abstract

15 This study aimed to document the prevalence of chronic equine piroplasmosis (EP) in poorly
16 performing Standardbred racehorses and to explore associations between the disease and sex, age
17 and hematological parameters. Blood was collected between 2004 and 2018; blood cell counts were
18 performed using a cell counter analyser, biochemical parameters using a photometer, and serum
19 proteins using agarose gel electrophoresis. Blood smears were prepared, coloured with a modified
20 Giemsa, and an experienced technician identified the presence of protozoa. The horses were
21 categorised into piroplasmosis positive (PP) and piroplasmosis negative (PN). The studied
22 population included 520 horses (142 female, 27.6%; CI 23.8% - 31.7%), with a median age of 4
23 (IQR 3 to 8) years. The prevalence of EP was 9.3% (CI: 6.9% - 12.1%). There was no association
24 between the infectious status and signalment. In Italian poorly performance Standardbreds, chronic
25 piroplasmosis caused mild normocytic, normochromic anemia, hyperbilirubinemia,
26 thrombocytopenia and hypergammaglobulinemia, as reported in literature. However, our findings
27 suggests that blood analysis needs to be interpreted with caution as there were cases with overlap
28 between parameters in PP and PN horses, and normal ranges. Hence, in cases of poorly performing
29 Standardbreds living or recently moving into an EP endemic region, blood cytology should be
30 performed as a first step in differential diagnosis procedures to exclude chronic EP as one possible
31 cause for poor performance. Further diagnostic tests (i.e. PCR, ELISA) are also recommended
32 because correct diagnosis is vital to ensure the criteria of “lack of disease” in the principle of good
33 health.

34
35 **Keywords:** poor performance; hematology; diagnosis; health; welfare

36

37 1. Introduction

38 Equine piroplasmosis (EP) is a blood-borne disease caused by *Babesia caballi* and *Theileria equi*
39 [1]. Worldwide, EP has an economic impact on the horse industry, and horses must be tested for EP
40 before travelling internationally [2]. EP is endemic in tropical and subtropical areas, including all of
41 the Mediterranean Region [1]. However, some countries (e.g. USA) are EP free and movements of
42 horses is the highest risk factor for spreading the disease into these areas [3]. EP is endemic in Italy;
43 whilst *Theileria equi* has been identified the most prevalent species, some horses were found
44 infected with *Babesia caballi*, *Babesia canis*, *Theileria annae*, *Theileria sergenti* and *Theileria*
45 *buffeli* [4, 5]. EP can manifest in hyperacute, acute, subacute and chronic forms [6]. The acute form
46 causes fever, lethargy, petechiations on mucous membranes, icterus, pigmenturia and severe
47 anemia, and the hyperacute form can be fatal [7]. Hyperacute cases are usually due to *T. equi*
48 affecting naïve horses introduced into an EP endemic region [6]. Horses with subacute form show
49 less severe clinical signs, with similarities to the acute form [5]. Chronic infection, mainly due to *T.*
50 *equi* or *B. Caballi*, results in non-specific signs, including lethargy, partial anorexia, weight loss,
51 and poor performance [6, 7]. Chronic EP may be difficult to diagnose and consequently the
52 prevalence underestimated.

53 Poor performance is a common problem in racing horses. A definitive diagnosis is often difficult to
54 reach and requires a complete evaluation, including laboratory tests, respiratory scoping, cardiac
55 examination and dynamic evaluation on the high speed treadmill [8, 9]. Furthermore, it has been
56 reported that poor performing racehorses were kept in training, and were over trained in the hope of
57 improving performance [10]. Appropriate differential diagnostic procedures, and avoiding
58 strenuous exercise of an animal that could be affected by a systemic and/or infectious disease,
59 would be vital to safeguard the principle of “good health” within the welfare quality system [11].
60 Whilst EP is endemic in Italy and its chronic form is difficult to diagnose as the clinical signs are
61 unreliable [6], it was hypothesized that chronic EP could be one of the agents associated with poor

62 performance in Italian Standardbred racehorses, and should be included as a differential diagnosis
63 in this population.

64 To the best of the authors' knowledges, there are no studies investigating the epidemiology of
65 chronic piroplasmosis in Standardbred horses in Southern Italy. The aims of this study were
66 therefore to document the prevalence of chronic piroplasmosis in poorly performing Standardbred
67 racehorses and to explore associations between the infectious status, horse signalment and
68 hematological parameters.

69

70 **2. Materials and Methods**

71 We reviewed the results of 520 complete blood counts of Standardbred horses that were examined
72 from 2004 to 2018 for poor performance.

73 The horses' blood was sampled and physical examinations were carried out in accordance with the
74 EU Directive 2010/63/EU regarding the protection of animals used for scientific purposes. Physical
75 examination and blood sampling procedures were explained to horse owners and written informed
76 consent was obtained to use the collected data.

77 **2.1 Horses, blood sampling and**

78 All the horses were stabled and trained in Southern Italy, under traditional management and training
79 regime [12]. Briefly, horses were usually kept at the race track or in private horse stables and
80 housed in a single box, without access to pasture and with limited access to paddocks (maximum 2
81 hours/daily). The diet was based on commercial food (40%) and oaten hay (60%). Horses were
82 under intense training and were raced at least twice monthly. Veterinary examination was requested
83 by the trainer if the horse displayed poor performance in either training or racing.

84 The same veterinarian (BP) collected blood samples from the external jugular vein in two tubes
85 with and without anticoagulant (EDTA) of the vacutainer system (Becton Dickinson. Franklin
86 Lakes, NJ). Blood was collected in the morning, before feeding and training, while the horses were
87 at rest and unrestrained in their stalls. The blood samples were collected at least three days after

88 racing or strenuous exercise; the day before sampling each horse was trained slowly (40 minutes at
89 4-5 m/sec). The horses were not receiving concurrent medication (e.g. corticosteroid or anti-
90 inflammatory).

91 **2.2 Blood analysis**

92 After collection, blood samples were kept at 4°C and analysed within 4 hours at the Laboratory of
93 the Department of Emergency and Organ Transplantation (Bari University, Italy). Hematocrit
94 (HCT) values were determined after centrifugation at 12000 rpm/16128 CFT for five minutes and
95 read on a hematocrit reader card [13]. An air-dried smear of fresh blood was also prepared and
96 stained with a Romanowsky stain, specifically the Giemsa Stain. The blood films were placed in
97 absolute methyl alcohol for 10 min and air-dried, covered with Giemsa diluted with neutral distilled
98 water 1:10 for 60 min. and then washed [14]. Light microscopy was used to identify the organisms
99 (i.e. *Babesia caballi* and *Theileria equi*) within the erythrocytes (Fig. 1) by an experienced
100 technician (RL), and the samples were categorised into piroplasmosis positive (PP) and
101 piroplasmosis negative (PN).

102 Blood cell counts (BCC) were performed using the Abbott cell counter analyser CELL DYN 3700
103 (Veterinary Multi-species Hematology System, Abbott, Chicago, IL). The following parameters
104 were recorded: red blood cells (RBC) ($\times 10^6/\mu\text{l}$), hemoglobin (Hb) (g/dl), mean corpuscular volume
105 (MCV) (fl), mean corpuscular hemoglobin (MCH) (pg), mean corpuscular hemoglobin
106 concentration (MCHC) (g/dl), red blood cell distribution width (RDW)(%), white blood cells
107 (WBC) ($\times 10^3/\mu\text{l}$), neutrophils (N) (%), lymphocytes (L) (%), monocytes (M) (%), eosinophils (E)
108 (%), and basophils (B) (%), platelets ($\times 10^3/\mu\text{l}$).

109 Serum was obtained by centrifugation (1600 x g for 15 min) and the following parameters were
110 determined: total serum proteins (TP, g/dl), aspartate aminotransferase (AST, IU/L), alanine
111 transaminase ALT (IU/L), gamma-glutamyltransferase (GGT, IU/L), alkaline phosphatase (ALP,
112 IU/L), creatine kinase (CK, IU/L), lactate dehydrogenase (IU/L), total bilirubin (mg/dl), cholesterol
113 (mg/dl), triglycerides (mg/dl), urea (mg/dl), creatinine (mg/dl), glucose (mg/dl), calcium (mg/dl),

phosphorus (mg/dl), magnesium (mg/dl), choride (mEq/L). Biochemical parameters were assessed with ASSEL reagents and the SEAC photometer with interferential filters. Serum protein electrophoresis was performed on agarose gel, according to the Helena BioSciences method [15].

2.3 Treatment and follow-up

Piroplasmosis positive horses (PP) were treated with imidocarb propionate (2.2 mg/kg, Carbesia®, 85 mg/ml), twice at 48 hours' interval, as suggested in literature [1]. Follow-up of PP horses was carried out at 4 weeks after the initial blood sampling occasion. Follow-up included a clinical examination and the same blood analysis.

2.4. Statistical analysis

Descriptive statistics was performed on signalment data and haematological, biochemical and assay parameters. Categorical data were presented as numbers, percentages and 95% confidence intervals (CI), whist continuous data were presented as medians and interquartile ranges (IQR). Associations between parameters and infection status (piroplasmosis positive (PP) and piroplasmosis negative (PN)) determined using non-parametric Wilcoxon Rank sum test. The association between positive animals and possible risk factors (age, sex) was evaluated using chi square test. All statistical analysis were performed using Genstat 19th edition and P value was set at 0.05.

3. Results

In total 520 horses were sampled, of which 142 (27.6%; 95% CI 23.8% to 31.7%) were female. At the time of sampling, horses were a median of 4 years of age (IQR 3 to 8; maximum 10). The prevalence of EP was 9.2% (95% CI 6.9% to 12.1%). No association was found between the infectious status and age or sex (P=0.205, and P=0.572, respectively).

3.1 Haematology

Table 1 shows the results of BCC in PP and PN horses. PP horses showed mild normocytic, normochromic anemia, and thrombocytopenia. No difference were present in the white blood cells.

3.2 Biochemical parameters

139 Table 2 shows the results of the biochemical profile in PP and PN horses. PP horses showed
140 hyperbilirubinemia, and their GGT, ALT and CK levels were lower than those of PP horses.
141 However, the liver and muscle enzymes activities of both PP and PN horses were within the normal
142 range. Glycaemia was higher in PP than in PN ($P<0.001$). There were no differences between PP
143 and NP horses and the other variables.

144 3.3 Electrophoresis of proteins

145 Table 3 shows the results of the serum protein electrophoresis in PP and PN horses. PP horses
146 showed an increase in alpha 2 and gamma globulins in comparison with NP horses and normal
147 range. There were no differences between PP and NP horses and the other variables.

148 3.4 Follow-up

149 PP horses were reported by trainers to have returned to acceptable performance by the time of
150 follow-up. Light microscopy was negative and blood parameters were within the normal range
151 [16,17].

152

153 4. Discussion

154 The current study investigated the prevalence of chronic EP in poorly performing Standardbred
155 racehorses and explored associations between the infection status, horse signalment and
156 hematological parameters. The prevalence of EP in the studied population was nearly 10% and
157 while sex and age were not associated with EP, significant associations between infection status and
158 RBC, PLT, bilirubin and globulin levels were found. Further, after being treated for EP, horses
159 returned to their previous level of performance in training. This finding supports our hypothesis
160 that in an EP endemic region, EP should be considered as one of the possible causes of poor
161 performance and should be included as a first step of the differential diagnosis procedures. “Lack of
162 disease” is one of the criteria of good health in the Animal Welfare Quality system, and offering the

appropriate diagnosis is one of the duties of veterinarians, who should always work safeguarding the health and welfare of their patients, avoiding protracted and useless sufferance [11, 20]. Numerous studies have been published regarding the epidemiology and distribution of EP in specific countries and regions [6, 7]. In Italy, EP prevalence ranges from 8.5% [21] to 86.4% [5]. The prevalence varied depending on the experimental design, sample population and diagnostic testing procedure. In a study conducted in Piedmont Region, Northwestern Italy, the prevalence of EP in a population of 135 horses randomly selected was of 17% using semi-nested PCR [4]. In a study conducted on 412 horses reared in Central and Northern Italy the seroprevalence was of 68.4%, with 3.1% and 9.4% of samples positive to microscopy and PCR, respectively [22]. In a population of 303 horses living in Abruzzo and Marche (Central-Southern Italy) the prevalence EP was 14.2% using PCR and 18.7% using indirect immunofluorescence, with the majority of cases due to *T. equi* [23]. In addition, one-quarter of the infected horses showed poor performance [23]. Our results fall within the prevalence range previously reported for the country, but to our knowledge this is the first study dealing with only racing Standardbreds with poor performance living in Southern Italy.

Standardbreds in racing in Southern Italy live in single stalls. Breed has been identified as a risk factor, with trotters were found to be less likely to be infected in comparison with Italian heavy draught horses [22]. Grazing, presence of ticks on the animals, group housing and riding into bushes have been also identified as risk factors for EP [22, 24]. Therefore, it could be supposed that the prevalence reported in our study was lower than in other studies because the target population could have less exposure to the natural infection. However, it should be considered that the transmission of *T. equi* can occur also iatrogenically through inappropriate mixing of the infected and uninfected blood [6]. This occurs during the poor or unregulated practices, such as needle sharing and “blood doping”. Blood doping was implicated as the cause of an outbreak of EP in Florida among racing horses in 2008 [25]. It is possible that poor practices could have been one of the cause of

188 transmission in our racing horses, and these practices should be avoided and considered a threat for
189 the health and the welfare of Standardbreds in Italy.

190 No association between the infectious status and sex and age was found in our study. This is in
191 agreement with many other studies [24, 26, 27]. However, Moretti et al. [22] found that females
192 were infected more often than males and it is well known that naïve young animals were more
193 likely to develop clinical acute forms [6]. Our study focussed on chronic form of EP and this could
194 be the reason why we did not find sex or age as risk factors. Associations were found with RBC,
195 PLT, bilirubin, and globulins. Standardbreds affected by chronic EP developed mild normocytic,
196 normochromic anemia, thrombocytopenia, hyperbilirubinemia and hypergammaglobulinemia.
197 Anemia and thrombocytopenia were expected and in agreement with the literature [27, 28].
198 However, during the chronic form the effects could be very mild, so it is important to interpret the
199 RBC values taking into account the range of normality for this breed [16]. Further, some of the PP
200 horses had RBC values within the lower part of the normal range. EP usually causes a hemolytic
201 anemia, which explains the hyperbilirubinemia found in our and other studies [5]. In disagreement
202 with literature [5, 24], PP horses did not have increased enzyme activity. Instead, PP had lower
203 GGT, ALP and CK activity levels than NP horses. This could be due to the fact that NP were
204 affected by another cause of poor performance. However, since both PP and NP horses had enzyme
205 activity within the normal range, the difference found may be statistically significant, but not
206 biologically significant, and consequently not clinically relevant. The common clinical sign and
207 criterion to be included in the population investigated was poor performance, which was the reason
208 why our specialists were called by the trainers. This should be taken in account interpreting our
209 haematological results and could be the reason why overlaps between the parameters in PP and PN
210 horses occurred. The increase in γ globulins is in line with the chronic form of the infection [29, 30]
211 and with the response of the equine immune system to EP infection [6]. It is worth noting that in
212 endemic region, seropositive inapparent carriers are at risk of developing clinical EP in case of

213 concurrent disease or stress such as strenuous exercise [1]. Hence, considering that the relationship
214 between the infection with *T. equi*, stress and immune system is complex and not completely
215 defined [31], ensuring appropriate management and welfare standards to racing horses should be
216 recommended to minimise the prevalence of EP and subsequent poor performance syndrome and
217 the hematological alterations described.

218 A limitation of the current study was that EP was diagnosed using light microscopy. Within the
219 erythrocyte, *B. caballi* typically appears as 2 large (pear-shaped) merozoites, and during clinical
220 infection the percentage of erythrocytes parasitized is less than 1%. The *T. equi* merozoites are
221 smaller (Fig. 1) and the percent of infected erythrocytes during clinical diseases is usually between
222 1% and 5% but can reach 20% [6]. As the current study investigated chronic EP, and it has been
223 reported that microscopy is less sensitive than PCR [22], our prevalence is most likely
224 underestimated. The competitive inhibition enzyme-linked immunosorbent assay (cELISA) has
225 been one of the regulatory tests prescribed by the OIE for international horse transport [2].
226 Considering that PCR and ELISA are now a routine variable in commercial laboratory [25], in case
227 of a horse with a haematological picture referable to EP resulted negative to blood cytology,
228 knowing that it could be a possible false negative at microscopy, PCR and ELISA should be
229 requested. However, light microscopy remains a useful, simple and cheap screening and should be
230 recommended as a first step in the differential diagnosis procedure.

231 Another limitation is that this study only looks at EP as one possible cause of poor performance,
232 without excluding other possible chronic diseases, and does not note the reason for poor
233 performance in horses not diagnosed with EP. Further, we did not differentiate between *B. caballi*
234 and *T. equi* infection, which was not always possible by microscopy and could have been done
235 using serology or using a specific polymerase chain reaction. As the study was conducted over a 15
236 year time period, it was impossible to store and retest the samples to differentiate between species.

237 Notwithstanding those limitations, this study has increased our knowledges of EP in a specific
238 target population..

239 **5. Conclusions**

240 The prevalence of chronic form of EP was of 9.3% in poorly performing Standardbred racehorses
241 living in Southern Italy. Accurate diagnostic procedures were required to identify cases of poorly
242 performing horses suffering from this form of piroplasmosis to ensure the criteria of “lack of
243 disease” in the principle of good health, and therefore maintain good welfare. Blood tests and blood
244 cytology should be recommended as a first step of diagnosis when a Standardbred living in a EP
245 endemic zone is not performing well. However, in the event that the organisms are not seen in the
246 blood smear but hematology results show mild anemia, hyperbilirubinemia and
247 hypergammaglobulinemia, further laboratory tests (i.e. ELISA and PCR) should be performed to
248 reach an accurate diagnosis.

249

250 **Conflicts of Interest**

251 The authors declare no conflict of interest

252 **Author contribution**

253 Conceptualization: BP, RL, GR; Methodology: BP, RL, GR, CDT; Formal Analysis: CDB, RL,
254 GR; Data Curation: BP, SMR ; Writing-Original Draft Preparation: BP; Writing-Review & Editing:
255 GR, SMR; Supervision: GR; Funding Acquisition: BP, GR.

256 **Funds**

257 Internal funds of the University of Bari, Italy

258 **References**

- 259 [1] Tamzali Y. Equine piroplasmosis: An updated review. Equine Veterinary Education. 2013;25:590-8.
260 [2] OIE. Handbook for the management of high health, high performance horses. OIE: FEI; 2016.

261 [3] Herholz C, Füssel AE, Timoney P, Schwermer H, Bruckner L, Leadon D. Equine travellers to the Olympic
 262 Games in Hong Kong 2008: A review of worldwide challenges to equine health, with particular reference to
 263 vector-borne diseases. *Equine Veterinary Journal*. 2008;40:87-95.

264 [4] Zanet S, Bassano M, Trisciuglio A, Taricco I, Ferroglio E. Horses infected by Piroplasms different from
 265 *Babesia caballi* and *Theileria equi*: species identification and risk factors analysis in Italy. *Veterinary*
 266 *Parasitology*. 2017;236:38-41.

267 [5] Zobba R, Ardu M, Niccolini S, Chessa B, Manna L, Cocco R, et al. Clinical and laboratory findings in equine
 268 piroplasmosis. *Journal of Equine Veterinary Science*. 2008;28:301-8.

269 [6] Wise L, Kappmeyer L, Mealey R, Knowles D. Review of equine piroplasmosis. *Journal of Veterinary*
 270 *Internal Medicine*. 2013;27:1334-46.

271 [7] De Waal D. Equine piroplasmosis: a review. *Br Vet J*. 1992;148:6-14.

272 [8] Martin Jr BB, Reef VB, Parente EJ, Sage AD. Causes of poor performance of horses during training,
 273 racing, or showing: 348 cases (1992–1996). *Journal of the American Veterinary Medical Association*.
 274 2000;216:554-8.

275 [9] Morris EA, Seeherman HJ. Clinical evaluation of poor performance in the racehorse: the results of
 276 evaluations. *Equine veterinary journal*. 1991;23:169-74.

277 [10] Padalino B, Rubino G, Centoducati P, Petazzi F. Training versus overtraining: evaluation of two
 278 protocols. *Journal of Equine Veterinary Science*. 2007;27:28-31.

279 [11] Dalla Costa E, Murray L, Dai F, Canali E, Minero M. Equine on-farm welfare assessment: A review of
 280 animal-based indicators. *Animal Welfare*. 2014;23:323-41.

281 [12] Padalino B, Depalo P, Tateo A, Centoducati P. La gestione del cavallo trottatore: indagine in Puglia.
 282 *Ippologia*. 2005;16:15-8.

283 [13] Turgeon M. Theory and Procedures: Clinical Haematology. 1999:99-112

284 [14] Jain N. The horse: normal hematology with comments on response to disease. *Schalm's veterinary*
 285 *hematology* 4th edition Philadelphia: Lea & Febiger. 1986:154-5.

286 [15] Riond B, Wenger-Riggenbach B, Hofmann-Lehmann R, Lutz H. Serum protein concentrations from
 287 clinically healthy horses determined by agarose gel electrophoresis. *Veterinary clinical pathology*.
 288 2009;38:73-7.

289 [16] Padalino B, Rubino G, Lacinio R, Petazzi F. Observations on the hematology of standardbred horses in
 290 training and racing in southern Italy. *Journal of Equine Veterinary Science*. 2014;34:398-402.

291 [17] Padalino B, Rubino G, Tateo A, Lacinio R, Petazzi F. Hematology and biochemistry in standardbred
 292 according to the race-category. *Ippologia*. 2010;21:19-27.

293 [18] Walton RM. Clinical Laboratory Data. In: Southwood L, editor. *Practical Guide to Equine Colic*. 2013:78-
 294 86.

295 [19] Dietz O, Huskamp B. *Handbuch: Pferdepraxis*: Enke; 1999.

296 [20] Freire R, Phillips CJ, Verrinder JM, Collins T, Degeling C, Fawcett A, et al. The importance of animal
 297 welfare science and ethics to veterinary students in Australia and New Zealand. *Journal of veterinary*
 298 *medical education*. 2017;44:208-16.

299 [21] Grandi G, Molinari G, Tittarelli M, Sassera D, Kramer LH. Prevalence of *Theileria equi* and *Babesia*
 300 *caballi* infection in horses from northern Italy. *Vector-Borne and Zoonotic Diseases*. 2011;11:955-6.

301 [22] Moretti A, Mangili V, Salvatori R, Maresca C, Scoccia E, Torina A, et al. Prevalence and diagnosis of
 302 *Babesia* and *Theileria* infections in horses in Italy: a preliminary study. *The Veterinary Journal*.
 303 2010;184:346-50.

304 [23] Di Corinto GJ, Bonfini B, Savini G, Gati A. Piroplasmosis nei Cavalli abruzzesi e marchigini. *Il progresso*
 305 *veterinario*. 2010;5:5.

306 [24] Sumbria D, Singla LD, Kumar S, Sharma A, Dahiya RK, Setia R. Spatial distribution, risk factors and
 307 haemato-biochemical alterations associated with *Theileria equi* infected equids of Punjab (India) diagnosed
 308 by indirect ELISA and nested PCR. *Acta Tropica*. 2016;155:104-12.

309 [25] Short MA, Clark CK, Harvey JW, Wenzlow N, Hawkins IK, Allred DR, et al. Outbreak of equine
 310 piroplasmosis in Florida. *Journal of the American Veterinary Medical Association*. 2012;240:588-95.

311 [26] Ferreira EP, Vidotto O, Almeida JC, Ribeiro LPS, Borges MV, Pequeno WHC, et al. Serological and
312 molecular detection of *Theileria equi* in sport horses of northeastern Brazil. *Comparative Immunology,*
313 *Microbiology and Infectious Diseases.* 2016;47:72-6.

314 [27] Díaz-Sánchez A, Fonseca-Rodríguez O, del Castillo-Domínguez S, Alfonso-Dorta Y, Lobo-Rivero E,
315 Corona-González B, et al. Hematological alterations found in horses (*Equus caballus*) infected with *Babesia*
316 *caballi* and *Theileria equi*. *Revista de Salud Animal.* 2018;40:1-10.

317 [28] Butler CM, Sloet van Oldruitenborgh-Oosterbaan MM, Stout TAE, van der Kolk JH, Wollenberg Lvd,
318 Nielen M, et al. Prevalence of the causative agents of equine piroplasmosis in the South West of The
319 Netherlands and the identification of two autochthonous clinical *Theileria equi* infections. *The Veterinary*
320 *Journal.* 2012;193:381-5.

321 [29] Murata H, Shimada N, Yoshioka M. Current research on acute phase proteins in veterinary diagnosis:
322 an overview. *The Veterinary Journal.* 2004;168:28-40.

323 [30] Murata H. Stress and acute phase protein response: An inconspicuous but essential linkage. *The*
324 *Veterinary Journal.* 2007;173:473-4.

325 [31] Takeet M, Adeleye A, Adebayo O, Akande F. Haematology and serum biochemical alteration in stress
326 induced equine theileriosis. A case report. *Science World Journal.* 2009;4:19-21

327

328

329 **Table 1.** Blood cell count results of poor performing Standardbred horses (n=520) with (PP) and
330 without (NP) chronic form of equine piroplasmosis. Results are expressed as median and
331 interquartile range (IQR)

	PP (n=48)	PN (n=472)	NR*	P
RBC (x10⁶/μl)	7.61 (IQR 6.71-8.71)	8.67 (IQR 7.89-9.82)	8.4-10.4	<0.001
Hb (g/dl)	12.0 (IQR 10.9-13.5)	13.4 (IQR 12.2-14.5)	12.7-15.7	<0.001
Hct (%)	32 (IQR 20-36)	37 (IQR 34-40)	36-42	<0.001
MCH (pg)	15.8 (IQR 15-16.4)	15.5 (IQR 14.7-16.3)	13.3-17.5	0.025
MCV (fl)	42.8 (IQR 41.4-43.9)	42.2 (IQR 39.9-43.9)	39.3-44.6	0.120
MCHC (g/dl)	36.8 (IQR 36.5-37.4)	37 (IQR 36.4-37.3)	36.3-37.5	0.927
RDW (%)	21.2 (IQR 20.5-22.4)	22.6 (IQR 21.5-24.1)	17-20	<0.001
WBC (x10³/μl)	8.2 (IQR 6.9-9.91)	8.2 (IQR 7.2-9.6)	6.51-9.59	0.927
N (%)	57.1 (IQR 49-62)	59.8 (51.6-66.9)	54.31-68.3	0.085
L (%)	37.5 (IQR 31-46)	35.9 (IQR 29-43)	25.15-37.7	0.294
E (%)	1 (IQR 0-1.5)	1 (IQR 0.1-2)	0.74-1.8	0.066
M (%)	2 (IQR 1-4.8)	2 (IQR 1-4.7)	2-8.11	0.994
B (%)	0 (IQR 0-0.2)	0 (IQR 0-0.2)	0-0.4	0.932
PLT (x10³/μl)	99.5 (IQR 81.1-125)	114 (92.1-139)	100-225	0.001

332 * Normal Range [16,

333333

334 **Table 2.** Biochemical profile results of poor performing Standardbred horses (n=520) with (PP) and
335 without (NP) chronic form of equine piroplasmosis. Results are expressed as median and
336 interquartile range (IQR).

	PP (n=48)	PN (n=472)	NR	P
Total Protein (g/dl)	6.7 (IQR 6.4-7.1)	6.8 (IQR 6.4-7.1)	6.27-7.1	0.986
AST (IU/L)	357 (IQR 253.8-471.2)	399 (IQR 310-585.5)	335-623	0.052
ALT (IU/L)	15 (IQR 9.7-20.2)	12 (IQR 8-18)	7-15	0.154
GGT (IU/L)	12.5 (IQR 8-12)	16 (IQR 12-22)	6-36	0.001
ALP (IU/L)	288 (IQR 227.5-329.5)	325.5 (IQR 259-405)	278-490	0.003
CK (IU/L)	149 (IQR 108-191)	172.5 (IQR 128-237.5)	116-316	0.007
LDH (IU/L)	530 (IQR 415.5-721.5)	527 (IQR 401-662)	394-680	0.635
Bilirubin (mg/dl)	3.92 (IQR 2.91-5.57)	2.63 (IQR 2.05-3.48) ¹	1-3	<0.001
Cholesterol (mg/dl)	83 (IQR 71-96.5)	80 (IQR 72-89.7)	63-97	0.277
Triglycerides (mg/dl)	21.3 (IQR 15.5-39)	25 (IQR 17.5-35.2)	17-45	0.388
Urea (mg/dl)	33.4 (IQR 27.0-36.8)	30.7 (IQR 25.9-36.4)	22-38	0.313
Creatinine (mg/dl)	1.4 (IQR 1.3-1.6)	1.5 (IQR 1.3-1.6)	1.1-1.7	0.445
Glucose (mg/dl)	110 (IQR 95-121)	96 (IQR 84-106)	75-115	<0.001
Calcium (mg/dl)	11.1 (IQR 10.5-11.7)	11.3 (IQR 10.7-11.8)	9.5-12	0.259
Phosphorus (mg/dl)	3.4 (IQR 2.9-3.8)	3.6 (IQR 3-4.1)	3.1-4.4	0.062
Magnesium (mg/dl)	2.0 (IQR 1.8-2.2)	2.0 (IQR 1.9-2.3)	1.9-2.4	0.159
Chlorine (mEq/L)	106.4 (IQR 72-111.2)	108.3 (IQR 101.9-115)	94-102	0.134

337 * Normal Range [17,

338338

339 **Table 3:** Serum protein electrophoresis results of poor performing Standardbred horses (n=520)
 340 with (PP) and without (NP) chronic form of equine piroplasmosis. Results are expressed as median
 341 and interquartile range (IQR).

	PP	PN	NR*	P
Albumin (%)	46.5 (IQR 43.3-50.7)	47.3 (43.7-50.6)	45-60	0.660
α1 (%)	2.4 (IQR 1.7-3.1)	2.2 (IQR 1.8-3.4)	4-6	0.324
α2 (%)	13.4 (IQR 11.6-13.4)	13.3 (IQR 11.9-14.7)	7-13	0.002
β1 (%)	8.0 (IQR 6.6-9.1)	8.5 (IQR 7.4-9.3)	7-9	0.217
β2 (%)	5.5 (IQR 4.3-7.2)	5.6 (IQR 4.5-7.0)	4.5-8.5	0.894
γ (%)	24.37 (IQR 21.12-27.04)	22.6 (IQR 19.74-25.50)	8-22	0.020

342 * Normal Range [15, 19]

343

344 Fig 1. Examples of blood smear microscopy

Table 1. Blood cell count results of poor performing Standardbred horses (n=520) with (PP) and without (NP) chronic form of equine piroplasmosis. Results are expressed as median and interquartile range (IQR)

	PP (n=48)	PN (n=472)	NR*	P
RBC (x10⁶/μl)	7.6 (IQR 6.71-8.71)	8.7 (IQR 7.89-9.82)	8.4-10.4	<0.001
Hb (g/dl)	12.0 (IQR 10.9-13.5)	13.4 (IQR 12.2-14.5)	12.7-15.7	<0.001
Hct (%)	32.0 (IQR 20-36)	37.0 (IQR 34-40)	36.0-42.0	<0.001
MCH (pg)	15.8 (IQR 15-16.4)	15.5 (IQR 14.7-16.3)	13.3-17.5	0.025
MCV (fl)	42.8 (IQR 41.4-43.9)	42.2 (IQR 39.9-43.9)	39.3-44.6	0.120
MCHC (g/dl)	36.8 (IQR 36.5-37.4)	37.0 (IQR 36.4-37.3)	36.3-37.5	0.927
RDW (%)	21.2 (IQR 20.5-22.4)	22.6 (IQR 21.5-24.1)	17-20	<0.001
WBC (x10³/μl)	8.2 (IQR 6.9-9.91)	8.2 (IQR 7.2-9.6)	6.5-9.6	0.927
N (%)	57.1 (IQR 49-62)	59.8 (51.6-66.9)	54.3-68.3	0.085
L (%)	37.5 (IQR 31-46)	35.9 (IQR 29-43)	25.1-37.7	0.294
E (%)	1.0 (IQR 0-1.5)	1.0 (IQR 0.1-2)	0.7-1.8	0.066
M (%)	2.0 (IQR 1-4.8)	2.0 (IQR 1-4.7)	2-8.1	0.994
B (%)	0 (IQR 0-0.2)	0 (IQR 0-0.2)	0-0.4	0.932
PLT (x10³/μl)	99.5 (IQR 81.1-125)	114 (92.1-139)	100-225	0.001

* Normal Range [16, 17]

Table 2. Biochemical profile results of poor performing Standardbred horses (n=520) with (PP) and without (NP) chronic form of equine piroplasmosis. Results are expressed as median and interquartile range (IQR).

	PP (n=48)	PN (n=472)	NR	P
Total Protein (g/dl)	6.7 (IQR 6.4-7.1)	6.8 (IQR 6.4-7.1)	6.3-7.1	0.986
AST (IU/L)	357 (IQR 253.8-471.2)	399 (IQR 310-585.5)	335-623	0.052
ALT (IU/L)	15 (IQR 9.7-20.2)	12 (IQR 8-18)	7-15	0.154
GGT (IU/L)	12.5 (IQR 8-12)	16 (IQR 12-22)	6-36	0.001
ALP (IU/L)	288 (IQR 227.5-329.5)	325.5 (IQR 259-405)	278-490	0.003
CK (IU/L)	149 (IQR 108-191)	172.5 (128-237.5)	116-316	0.007
LDH (IU/L)	530 (IQR 415.5-721.5)	527 (IQR 401-662)	394-680	0.635
Bilirubin (mg/dl)	3.9 (IQR 2.91-5.57)	2.6 (IQR 2.05-3.48)	1-3	<0.001
Cholesterol (mg/dl)	83 (IQR 71-96.5)	80 (IQR 72-89.7)	63-97	0.277
Triglycerides (mg/dl)	21.3 (IQR 15.5-39)	25 (IQR 17.5-35.2)	17-45	0.388
Urea (mg/dl)	33.4 (IQR 27.0-36.8)	30.7 (IQR 25.9-36.4)	22-38	0.313
Creatinine (mg/dl)	1.4 (IQR 1.3-1.6)	1.5 (IQR 1.3-1.6)	1.1-1.7	0.445
Glucose (mg/dl)	110 (IQR 95-121)	96 (IQR 84-106)	75-115	<0.001
Calcium (mg/dl)	11.1 (IQR 10.5-11.7)	11.3 (IQR 10.7-11.8)	9.5-12	0.259
Phosphorus (mg/dl)	3.4 (IQR 2.9-3.8)	3.6 (IQR 3.0-4.1)	3.1-4.4	0.062
Magnesium (mg/dl)	2.0 (IQR 1.8-2.2)	2.0 (IQR 1.9-2.3)	1.9-2.4	0.159
Choline (mEq/L)	106.4 (IQR 72-111.2)	108.3 (IQR 101.9-115)	94-102	0.134

* Normal Range [17, 18]

Table 3: Serum protein electrophoresis results of poor performing Standardbred horses (n=520) with (PP) and without (NP) chronic form of equine piroplasmosis. Results are expressed as median and interquartile range (IQR).

	PP	PN	NR*	P
Albumin (%)	46.5 (IQR43.3-50.7)	47.3 (43.7-50.6)	45-60	0.660
α1 (%)	2.4 (IQR 1.7-3.1)	2.2 (IQR 1.8-3.4)	4-6	0.324
α2 (%)	13.4 (IQR 11.6-13.4)	13.3 (IQR 11.9-14.7)	7-13	0.002
β1 (%)	8.0 (IQR 6.6-9.1)	8.5 (IQR 7.4-9.3)	7-9	0.217
β2 (%)	5.5 (IQR 4.3-7.2)	5.6 (IQR4.5-7.0)	4.5-8.5	0.894
γ (%)	24.37 (IQR 21.1-27.0)	22.6 (IQR 19.7-25.5)	8-22	0.020

* Normal Range [15,

